Precision BioSciences Inc (DTIL)

[jondoeuk]

It faces competition from other cell therapies. I know TT11 (an auto anti-CD30 CAR-T) is already in a pivotal trial for late stage cHL [1], late stage CD30+ NHL, as well as a potential second line therapy (plus four doses of Opdivo) in cHL.

TT11X (healthy donor EBVSTs, with the same CAR) is also being tested in CD30+ lymphomas [2]. NTLA is also moving forward a healthy donor anti-CD30 CAR-T [3]. Another potential benefit is addition engineering. In this, they added a chemokine receptor [4].

Refs:
1 https://www.globenewswire.com/en/news-release/2021/12/13/2351226/0/en/Tessa-Therapeutics-Announces-Positive-Data-from-Phase-2-Trial-of-Autologous-CD30-CAR-T-Therapy-TT11-in-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-at-2021-ASH-Annual-Meeting.html
2 https://www.globenewswire.com/en/news-release/2021/12/11/2350320/0/en/Tessa-Therapeutics-Showcases-Positive-Clinical-Data-from-Phase-1-Study-of-Off-the-Shelf-CD30-Cell-Therapy-at-2021-Annual-Meeting-of-American-Society-of-Hematology-ASH.html
3 https://www.globenewswire.com/en/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html
4 https://ashpublications.org/blood/article/138/Supplement%201/742/480022/CD30-Directed-CAR-T-Cells-Co-Expressing-CCR4-in